Idaho is currently home to 368 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boise, Meridian, Idaho Falls and Nampa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054
Recruiting
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/26/2024
Locations: Saint Alphonsus Regional Medical Center, Boise, Idaho
Conditions: Breast Neoplasms
Register for Updates
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
NCT06373146
Recruiting
The main purpose of this study is to determine if combining tirzepatide with the mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 72 weeks and may include up to 19 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: Solaris Clinical Research, Meridian, Idaho
Conditions: Obesity
Register for Updates
A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: Treasure Valley Medical Research, Boise, Idaho
Conditions: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Register for Updates
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013
Recruiting
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: Care Research, Boise, Idaho
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Register for Updates
Mobile Health for Adherence in Breast Cancer Patients
NCT06112613
Recruiting
This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to enhanced usual care (EUC), where patients only use the WiseBag, to monitor medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor. To ensure CDK4/6 inhibitors achieve their full clinical benefit, patients need to take th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Breast Carcinoma, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Register for Updates
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age
NCT05436834
Recruiting
This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concerns (VOCs) in participants aged 6 months to <6 years, when administered as a primary series in SARS-CoV-2 vaccine-naïve participants (Part 1) and a single booster dose (BD) given to participants who previously received 2 doses of the mRNA-1273 vaccine as a primary series (Part 2); and will evaluate the safety and immunogenicity of th... Read More
Gender:
All
Ages:
Between 6 months and 5 years
Trial Updated:
05/24/2024
Locations: Velcocity Clinical Research, Meridian, Idaho
Conditions: SARS-CoV-2
Register for Updates
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
NCT04232553
Recruiting
The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: Grand Teton Research Group, Idaho Falls, Idaho
Conditions: Crohn's Disease
Register for Updates
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
NCT04379570
Recruiting
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treat... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8
Register for Updates
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
NCT06115499
Recruiting
This phase II/III trial compares the effect of the 3-drug chemotherapy combination of nab-paclitaxel, gemcitabine, plus cisplatin versus the 2-drug chemotherapy combination of nab-paclitaxel plus gemcitabine for the treatment of patients with pancreatic cancer that has spread to other places in the body (metastatic) and a known genetic mutation in the BRCA1, BRCA2, or PALB2 gene.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/22/2024
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Conditions: Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Squamous Cell Carcinoma, Stage IV Pancreatic Cancer AJCC v8
Register for Updates
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
NCT05976763
Recruiting
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. When zanubrutinib is used... Read More
Gender:
All
Ages:
60 years and above
Trial Updated:
05/22/2024
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Conditions: Mantle Cell Lymphoma
Register for Updates
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
NCT05710406
Recruiting
This phase II/III trial compares treatment with encorafenib and cetuximab to usual care (patient observation) for reducing the chance of cancer recurrence after standard surgery and chemotherapy in patients with BRAF-mutated stage IIB-III colon cancer. Encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor ce... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/22/2024
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Conditions: Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Stage III Colon Cancer AJCC v8
Register for Updates
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
NCT05673148
Recruiting
This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for patients who are not participating in a study is treatment with intravenous (IV) (through a vein) and/or oral medications (systemic therapy) to help stop the cancer sites from getting larger and the spread of the cancer to additional body sites. Ablative means... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/22/2024
Locations: Saint Luke's Cancer Institute - Boise, Boise, Idaho
Conditions: Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
Register for Updates